• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The protein binding of methotrexate by the serum of normal subjects.

作者信息

Steele W H, Lawrence J R, Stuart J F, McNeill C A

出版信息

Eur J Clin Pharmacol. 1979 Jun 12;15(5):363-6. doi: 10.1007/BF00558441.

DOI:10.1007/BF00558441
PMID:456408
Abstract

The protein binding of methotrexate by serum from eight normal volunteers was assessed by continuous ultrafiltration at pH 7.4 and 37 degrees C. Methotrexate concentrations were measured by radioimmunoassay and the data analysed by the method of Scatchard. The major binding protein was albumin which bound 87.3% of the drug in serum. Analysis of the Scatchard plots indicated two distinct groups of binding sites. Class I was found to have 0.16 +/- 0.05 (S D) binding sites with an intrinsic association constant of 71.15 +/- 35.98 (S D) X 10(4) M-1: Class II had 2.01 +/- 0.93 (S D) binding sites and and affinity of 0.18 +/- 0.15 X 10(4) M-1. No great change in the percentage of methotrexate bound occurred until the total concentration of the drug exceeded 50 muMol 1-1.

摘要

相似文献

1
The protein binding of methotrexate by the serum of normal subjects.
Eur J Clin Pharmacol. 1979 Jun 12;15(5):363-6. doi: 10.1007/BF00558441.
2
Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage.甲氨蝶呤在正常人血清中的蛋白结合:药物浓度、pH值、温度及储存的影响
J Pharmacol Methods. 1981 May;5(3):203-13. doi: 10.1016/0160-5402(81)90088-7.
3
Protein binding of methotrexate to human albumin and serum. A first derivative spectroscopic analysis.甲氨蝶呤与人白蛋白及血清的蛋白质结合:一阶导数光谱分析
Arzneimittelforschung. 1991 Dec;41(12):1286-8.
4
Alterations of phenytoin protein binding with in vivo haemodialysis in dialysis encephalopathy.透析性脑病中苯妥英蛋白结合率与体内血液透析的关系改变
Eur J Clin Pharmacol. 1979 Feb 19;15(1):69-71. doi: 10.1007/BF00563560.
5
The protein binding of methotrexate in the serum of patients with neoplastic disease.甲氨蝶呤在肿瘤疾病患者血清中的蛋白结合情况。
Cancer Chemother Pharmacol. 1981;7(1):61-4. doi: 10.1007/BF00258215.
6
Melphalan concentration dependent plasma protein binding in healthy humans and rats.美法仑在健康人类和大鼠体内的血浆蛋白结合呈浓度依赖性。
Eur J Clin Pharmacol. 1987;32(2):179-85. doi: 10.1007/BF00542192.
7
Methotrexate binding to human plasma proteins.
Pol J Pharmacol Pharm. 1990 Mar-Apr;42(2):151-7.
8
Distribution of 7-hydroxymethotrexate in human blood.7-羟基甲氨蝶呤在人体血液中的分布。
J Pharm Pharmacol. 1988 Jan;40(1):50-2. doi: 10.1111/j.2042-7158.1988.tb05149.x.
9
Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration.
Eur J Clin Pharmacol. 1985;28(3):339-45. doi: 10.1007/BF00543334.
10
Characterization of drug-protein binding process by employing equilibrium sampling through hollow-fiber supported liquid membrane and Bjerrum and Scatchard plots.通过中空纤维支撑液膜平衡采样以及比耶鲁姆和斯卡查德图对药物-蛋白质结合过程进行表征。
J Pharm Biomed Anal. 2008 Sep 10;48(1):49-56. doi: 10.1016/j.jpba.2008.04.030. Epub 2008 May 8.

引用本文的文献

1
Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.体外治疗甲氨蝶呤中毒:EXTRIP 工作组的系统评价和建议。
Clin J Am Soc Nephrol. 2022 Apr;17(4):602-622. doi: 10.2215/CJN.08030621. Epub 2022 Mar 2.
2
Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.ABCC2 和 ABCC3 基因敲除鼠模型中,甲氨蝶呤的剂量依赖性处置。
Drug Metab Dispos. 2011 Nov;39(11):2155-61. doi: 10.1124/dmd.111.041228. Epub 2011 Aug 12.
3
Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate.

本文引用的文献

1
Potential effect of the plasma on drug distribution.血浆对药物分布的潜在影响。
Nature. 1965 Jul 17;207(994):274-6. doi: 10.1038/207274a0.
2
Intermittent high dose oral methotrexate therapy in psoriasis.银屑病的间歇性高剂量口服甲氨蝶呤疗法。
Br J Dermatol. 1970 Jan;82(1):65-9. doi: 10.1111/j.1365-2133.1970.tb02194.x.
3
The effect of organic acids on renal clearance of methotrexate in man.
Clin Pharmacol Ther. 1969 Nov-Dec;10(6):849-57. doi: 10.1002/cpt1969106849.
类风湿关节炎患者长期接受小剂量甲氨蝶呤治疗时的血小板减少症。
Clin Rheumatol. 1996 May;15(3):266-70. doi: 10.1007/BF02229705.
4
Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate.
Clin Rheumatol. 1996 Mar;15(2):163-7. doi: 10.1007/BF02230334.
5
Pharmacokinetics of different doses of methotrexate at steady state by in situ microdialysis in a rat model.
Cancer Chemother Pharmacol. 1995;36(4):283-9. doi: 10.1007/BF00689044.
6
The protein binding of methotrexate in the serum of patients with neoplastic disease.甲氨蝶呤在肿瘤疾病患者血清中的蛋白结合情况。
Cancer Chemother Pharmacol. 1981;7(1):61-4. doi: 10.1007/BF00258215.
7
Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion.多次剂量输注后兔体内甲氨蝶呤和7-羟基甲氨蝶呤的清除率研究。
J Pharmacokinet Biopharm. 1983 Oct;11(5):515-27. doi: 10.1007/BF01062209.
8
Clinical pharmacokinetics of commonly used anticancer drugs.常用抗癌药物的临床药代动力学
Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002.
9
Melphalan concentration dependent plasma protein binding in healthy humans and rats.美法仑在健康人类和大鼠体内的血浆蛋白结合呈浓度依赖性。
Eur J Clin Pharmacol. 1987;32(2):179-85. doi: 10.1007/BF00542192.
10
Antineoplastic drugs in 1990. A review (Part II).1990年的抗肿瘤药物。综述(第二部分)。
Drugs. 1990 May;39(5):652-73. doi: 10.2165/00003495-199039050-00003.
4
Prolonged intravenous methotrexate therapy in the treatment of acute leukemia and solid tumors.甲氨蝶呤静脉延长疗法治疗急性白血病和实体瘤
Cancer Res. 1970 Aug;30(8):2132-8.
5
The metabolic fate of tritiated methotrexate. I. Absorption, excretion, and distribution in mice, rats, dogs and monkeys.
Cancer Res. 1965 Aug;25(7):1008-17.
6
Measurement of drug displacement by continuous ultrafiltration.通过连续超滤法测量药物置换。
J Pharm Sci. 1974 Feb;63(2):249-52. doi: 10.1002/jps.2600630215.
7
Improved therapeutic index of methotrexate with "leucovorin rescue".
Cancer Res. 1973 Jul;33(7):1729-34.
8
Recent advances in the chemotherapy of metastatic osteogenic sarcoma.转移性骨肉瘤化疗的最新进展
Cancer. 1972 Dec;30(6):1627-31. doi: 10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h.
9
Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck.大剂量甲氨蝶呤继以亚叶酸钙输注治疗头颈部癌的疗效
Cancer Res. 1968 Jun;28(6):1088-94.
10
Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue".甲氨蝶呤治疗头颈癌:通过使用亚叶酸钙“解救”提高治疗指数。
Cancer Res. 1970 Jun;30(6):1782-8.